Article
Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2013
Lee Victor H F, Tin Vicky P C, Choy Tim-shing, Lam Ka-on, Choi Cheuk-wai, Chung Lap-ping, Tsang Janice W H, Ho Patty P Y, Leung Dennis K C, Ma Edmond S K, Liu Jing, Shek Tony W H, Kwong Dora L W, Leung To-wai, Wong Maria P
Abstract excerpt
BACKGROUND: This study investigated whether there were differential survival outcomes to first-line tyrosine kinase inhibitors (TKI) in patients with metastatic non-small-cell lung cancer harboring different subtypes of exon 19 and exon 21 mutations on epidermal growth factor receptor (EGFR). METHODS: Of 452 patients with stage IIIB and IV non-small-cell lung cancer, 192 patients (42.5%) harbored EGFR mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.